Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
von willebrand factor + coagulation factor VIII
- Development stage
- Unknown
- Lead developer
- Octapharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Von Willebrand factor + coagulation factor VIII concentrate is a high-purity, double virus-inactivated, plasma-derived biologic containing human von Willebrand factor (VWF) and coagulation factor VIII (FVIII) in a physiological 1:1 ratio. Developed primarily by Octapharma (under the brand name Wilate), it is indicated for the treatment of hereditary and acquired von Willebrand disease (VWD) across all types (Type 1, 2, and 3) as well as hemophilia A. The therapy works by temporarily replacing the missing or dysfunctional clotting factors, thereby restoring normal platelet adhesion to damaged vascular endothelium and stabilizing the intrinsic coagulation cascade to control or prevent bleeding episodes.
- Brand names
- WilateHumate-PAlphanateVoncentoOptivateWilstart
- Other names
- von Willebrand Factor/Coagulation Factor VIII Complex (Human)antihemophilic factor/von Willebrand factor complex (human)
02
Targets
BB-031 (Von Willebrand factor)Coagulation Factor IXaF8 (Coagulation Factor VIIIa)GP1BA (Platelet glycoprotein ib alpha chain)
Beyond the preview
Go deeper on von willebrand factor + coagulation factor VIII.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on von willebrand factor + coagulation factor VIII.